ZNOM Znomics, Inc. featured news, full reports, and detailed charts
Znomics, Inc. (ZNOM/ZNOM.OB) Wrap Up:
Znomics, Inc. develops advanced zebrafish technologies and medicinal chemistry to accelerate drug discovery. The company focuses on identifying preclinical drug compounds and then collaborating with pharmaceutical companies for subsequent clinical development. Znomics' drug discovery efforts focus on three diseases areas: inflammation, cancer, and obesity. The company is also leveraging its technology platform for the benefit of pharmaceutical partners to derive and advance clinical drug candidates from their internal drug discovery programs. Its drug discovery platform is based on its catalogued library of mutations in the zebrafish, called the ZeneMark Library. The ZeneMark Library contain...Znomics, Inc. (ZNOM:OTC Bulletin Board Market)
Snapshot of Znomics, Inc. (ZNOM)
|
OPEN
--
|
PREVIOUS CLOSE
$0.05
|
|
|
DAY HIGH
--
|
DAY LOW
--
|
|
|
52 WEEK HIGH
01/16/09 - $0.25
|
52 WEEK LOW
08/14/09 - $0.01
|
|
|
MARKET CAP
526.3K
|
AVERAGE VOLUME 3 mo
6.9K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
11.7M
|
|
|
ZNOM Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
ZNOM Top Compensated Officers
Executives, Board Directors
Key developments for Znomics, Inc. (ZNOM)
On October 18, 2009, Dr. Mark A. Philip. PhD resigned as the Chief Executive Officer of Znomics, Inc., effective immediately. Dr. Philip will remain a director and advisor to Znomics. Dr. Philip will be compensated at a rate of $250 per hour for services performed as an advisor. Dr. Philip will not be entitled to any compensation for his service as a director. On October 21, 2009, the board of directors appointed Znomics's Chairman of the Board, Dr. Dwight Sangrey, as Chief Executive Officer effective immediately. Dr. Sangrey will not be entitled to any compensation for his service as Chief Executive Officer.
On September 23, 2008, Znomics Inc. announced the dismissal of Moore & Associates, Chartered, the independent registered public accounting firm previously engaged as the principal accountant to audit the company's financial statements and the company approved the engagement of Carver Moquist & O'Connor, LLC, an independent registered public accounting firm, as the new principal accountant to audit the company's financial statements.
Znomics Inc. announced that on June 3, 2009, Dr. Bruce A. Beutel, PhD resigned as the Chief Scientific Officer of the company, effective immediately. Due to the company's discontinuance of operations, the company does not intend to appoint a replacement chief scientific officer.
ZNOM Competitors
| Company | Last | Change |
| Summit Corporation | 6.61 GBX | -0.27 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | ZNOM | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 1.6x |
|
| Price/Book | 3.0x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 1.0x |
|
|
ZNOM |
||
ZNOM transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||